HomeMarkets Markets Amgen Wins Big With FDA, Analyst Sees Soaring Potential By news November 2, 2023 0 245 FacebookTwitterPinterestWhatsApp The FDA approval of Amgen, Inc’s (NASDAQ: AMGN) biosimilar version of Johnson & Johnson’s (NYSE: JNJ) psoriasis treatment, Stelara, for multiple …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected156,730FansLike396,312FollowersFollow2,310SubscribersSubscribe Latest Articles Hot Items China Will Soon Lose the Title of “World’s Manufacturer” Markets DOJ: Russia Aimed Propaganda at Gamers, Minorities to Swing 2024 Election Markets OpenAI is looking for new ways to pay its bills Markets More than 90 company executives, 100 law enforcement officials back Harris Markets CTEM: The next frontier in cybersecurity Load more